Business
BioMark Diagnostics Announces Uplisting to OTCQB Venture Market
Milestone strengthens transparency and credibility as the Company advances commercialization of its metabolomics technology platform Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (OTCQB: BMKDF) (FSE: 20B) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that its common shares have been officially approved for uplisting from the OTC Pink Open Market to the OTCQB Venture M
About this update from Biomark Diagnostics, Inc.
[{"type":"text","content":"Milestone strengthens transparency and credibility as the Company advances commercialization of its metabolomics technology platform","length":132,"tagName":"p","attribs":{"class":"nfSubHeading"},"className":""},{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (OTCQB: BMKDF) (FSE: 20B) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that its common shares have been officially approved for uplisting from the OTC Pink Open Market to the OTCQB Venture Market under the symbol "BMKDF" on May 8th, 2025. Additionally, the Company's common shares will maintain its eligibility for settlement through the Depository Trust Company ("DTC"), a subsidiary of the Depository Trust & Clearing Corp., which facilitates the electronic clearing and settlement of publicly traded companies in the United States.","length":759,"tagName":"p"},{"type":"text","content":"Trading on the OTCQB is expected to complement the Company's existing listing on the Canadian Securities Exchange (CSE) under its existing symbol "BUX" and no action is needed by current shareholders. Real-time quotes and market information on BioMark Diagnostics Inc. can be found at www.otcmarkets.com.","length":318,"tagName":"p"},{"type":"text","content":"Rashid Bux, President and CEO, said: "This is a significant milestone for the Company as we aim to increase our presence among American retail and institutional investors, thereby providing enhanced liquidity. As we move toward the commercial launch of our liquid biopsy test for lung cancer, trading on the OTCQB will make it easier for U.S. investors to discover and trade our stock, while benefiting from transparent pricing and reporting standards. The timing is opportune for BioMark, and we believe the uplisting will boost visibility to a broader universe of investors and provide improved liquidity for our stock as the Company seeks to expand its future operations in the US, starting with potential collaborations at some important comprehensive cancer screening centers."","length":792,"tagName":"p"},{"type":"text","content":"About OTCQB","length":11,"tagName":"p"},{"type":"text","content":"The OTCQB® Venture Market is ...